|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: P2RX7 |
Gene summary for P2RX7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | P2RX7 | Gene ID | 5027 |
| Gene name | purinergic receptor P2X 7 | |
| Gene Alias | P2X7 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q99572 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5027 | P2RX7 | HCC1 | Human | Liver | HCC | 1.04e-08 | 2.62e+00 | 0.5336 |
| 5027 | P2RX7 | HCC2 | Human | Liver | HCC | 1.54e-16 | 3.74e+00 | 0.5341 |
| 5027 | P2RX7 | HCC5 | Human | Liver | HCC | 5.13e-08 | 1.29e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
| GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
| GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
| GO:004603422 | Liver | HCC | ATP metabolic process | 198/7958 | 277/18723 | 8.30e-23 | 1.55e-20 | 198 |
| GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
| GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
| GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
| GO:000925922 | Liver | HCC | ribonucleotide metabolic process | 240/7958 | 385/18723 | 2.07e-15 | 1.51e-13 | 240 |
| GO:000915022 | Liver | HCC | purine ribonucleotide metabolic process | 226/7958 | 368/18723 | 1.36e-13 | 7.69e-12 | 226 |
| GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
| GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
| GO:009719122 | Liver | HCC | extrinsic apoptotic signaling pathway | 143/7958 | 219/18723 | 6.99e-12 | 2.97e-10 | 143 |
| GO:004346722 | Liver | HCC | regulation of generation of precursor metabolites and energy | 89/7958 | 130/18723 | 1.84e-09 | 5.35e-08 | 89 |
| GO:005149522 | Liver | HCC | positive regulation of cytoskeleton organization | 138/7958 | 226/18723 | 1.26e-08 | 3.12e-07 | 138 |
| GO:003253522 | Liver | HCC | regulation of cellular component size | 217/7958 | 383/18723 | 1.28e-08 | 3.14e-07 | 217 |
| GO:000609022 | Liver | HCC | pyruvate metabolic process | 73/7958 | 106/18723 | 3.52e-08 | 7.82e-07 | 73 |
| GO:001605222 | Liver | HCC | carbohydrate catabolic process | 99/7958 | 154/18723 | 3.79e-08 | 8.30e-07 | 99 |
| GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
| GO:000918522 | Liver | HCC | ribonucleoside diphosphate metabolic process | 72/7958 | 106/18723 | 1.05e-07 | 2.03e-06 | 72 |
| GO:004603122 | Liver | HCC | ADP metabolic process | 63/7958 | 90/18723 | 1.17e-07 | 2.25e-06 | 63 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| P2RX7 | SNV | Missense_Mutation | novel | c.892N>C | p.Tyr298His | p.Y298H | Q99572 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| P2RX7 | SNV | Missense_Mutation | rs28360451 | c.556N>A | p.Glu186Lys | p.E186K | Q99572 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| P2RX7 | insertion | In_Frame_Ins | novel | c.1023_1024insACCTTGTATGGAGAAATGATAGCCCTTCAGTGGGTC | p.Leu341_Ser342insThrLeuTyrGlyGluMetIleAlaLeuGlnTrpVal | p.L341_S342insTLYGEMIALQWV | Q99572 | protein_coding | TCGA-B6-A0IM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| P2RX7 | SNV | Missense_Mutation | rs200840067 | c.1744C>T | p.Pro582Ser | p.P582S | Q99572 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| P2RX7 | SNV | Missense_Mutation | rs760498473 | c.361N>A | p.Glu121Lys | p.E121K | Q99572 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| P2RX7 | SNV | Missense_Mutation | c.652N>G | p.Phe218Val | p.F218V | Q99572 | protein_coding | deleterious(0.01) | possibly_damaging(0.89) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| P2RX7 | SNV | Missense_Mutation | rs200025457 | c.380N>T | p.Thr127Met | p.T127M | Q99572 | protein_coding | deleterious(0.01) | probably_damaging(0.911) | TCGA-CK-6747-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| P2RX7 | SNV | Missense_Mutation | c.526N>A | p.Ala176Thr | p.A176T | Q99572 | protein_coding | tolerated(0.43) | benign(0.077) | TCGA-CM-6165-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| P2RX7 | SNV | Missense_Mutation | novel | c.202A>G | p.Ile68Val | p.I68V | Q99572 | protein_coding | tolerated(1) | benign(0.011) | TCGA-D5-6539-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| P2RX7 | SNV | Missense_Mutation | rs149639375 | c.791N>A | p.Arg264His | p.R264H | Q99572 | protein_coding | tolerated(0.1) | possibly_damaging(0.489) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Pyridazinone derivative 1 | |||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | CHEMBL3545206 | GSK1482160 | ||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | 387065584 | ||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Thiazole-fused cycloalkyl carboxamide derivative 1 | |||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Piperazine derivative 6 | |||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Quinoline derivative 11 | |||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | PMID27724045-Compound-15 | |||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | allosteric modulator | 315661107 | ||
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL3545108 | AZD9056 | |
| 5027 | P2RX7 | NUCLEAR HORMONE RECEPTOR, ION CHANNEL, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Quinoline derivative 10 |
| Page: 1 2 3 4 5 6 7 8 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |